Show simple item record

dc.contributor.authorOdongo, Charles Okot
dc.contributor.authorOdida, Michael
dc.contributor.authorWabinga, Henry
dc.contributor.authorObua, Celestino
dc.contributor.authorByamugisha, Josaphat
dc.date.accessioned2022-08-17T09:59:13Z
dc.date.available2022-08-17T09:59:13Z
dc.date.issued2016
dc.identifier.citationOdongo, C. O., Odida, M., Wabinga, H., Obua, C., & Byamugisha, J. (2016). Burden of placental malaria among pregnant women who use or do not use intermittent preventive treatment at Mulago Hospital, Kampala. Malaria Research and Treatment, 2016.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/2382
dc.description.abstractIntermittent preventive treatment of malaria in pregnancy with sulphadoxine-pyrimethamine (SP-IPTp) is widely used to reduce the incidence of adverse pregnancy outcomes. As a monitor for continued effectiveness of this intervention amidst SP resistance, we aimed to assess malaria burden among pregnant women who use or do not use SP-IPTp. In a descriptive cohort study at Mulago Hospital, Kampala, 87 women who received two supervised doses of SP-IPTp were followed up until delivery. Controls were pregnant women presenting in early labour without history of SP-IPTp. Histopathological investigation for placental malaria (PM) was performed using the Bulmer classification criterion. Thirty-eight of the 87 women returned for delivery and 33 placentas were successfully collected and processed along with 33 placentas fromSP nonusers.Overall, 12% (4/33) of the users had evidence of PM compared to 48% (16/33) of nonusers. Among nonusers, 17/33, 8/33, 2/33, and 6/33 had no placental infection, active infection, active-chronic infection, and past-chronic infection, respectively. Among users, respective proportions were 29/33, 2/33, 0/33, and 2/33. No difference in birth weights was apparent between the two groups, probably due to a higher proportion of infections occurring later in pregnancy. Histological evidence here suggests that SP continues to offer substantial benefit as IPTp.en_US
dc.description.sponsorshipGrant no. 5R24TW008886 United States of America: Office of the US Global Aids Coordinator (OGAC), National Institutes of Health (NIH), and Health Resources and Services Administration (HRSA).en_US
dc.language.isoen_USen_US
dc.publisherMalaria Research and Treatmenten_US
dc.subjectMalariaen_US
dc.subjectPregnant Womenen_US
dc.subjectTreatmenten_US
dc.subjectPregnancy outcomesen_US
dc.titleBurden of Placental Malaria among Pregnant Women Who Use or Do Not Use Intermittent Preventive Treatment at Mulago Hospital, Kampalaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record